Answers are grounded in this paper and cite their sources.
This article examines the newly categorized advanced regenerative medicine treatment in South Korea, highlighting similarities with Japan's regulatory framework.
South Korea's Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products, enacted in 2019, was recently amended. This article examines the new advanced regenerative medicine treatment (ARMT) category, focusing on patient access, review processes, safety monitoring, ethical safeguards, and lessons from Japan's comparable framework.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: